Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00384332 · ClinicalTrials.gov registry record · Phase 4

Medication, Weight Gain and GI Hormones

A Phase 4 study, sponsored by Vanderbilt University.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target

NCT00384332 is a Phase 4 study that has completed, run by Vanderbilt University. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00384332, a Phase 4 study, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target

Study Summary

This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication. Both medications are used to treat depressed bipolar patients. The main focus of this study is the comparison of these two medications on gastro-intestinal hormones and weight gain.

Interventions

  • DRUG orally-disintegrating olanzapine
  • DRUG regular olanzapine

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2007-01
Est. Completion 2010-03
Phase Phase 4

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT00384332

The ClinicalTrials.gov registry entry for NCT00384332 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which orally-disintegrating olanzapine is the first listed.

NCT00384332 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00384332 about?

NCT00384332 is a clinical study titled "Medication, Weight Gain and GI Hormones". This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication. Both medications are used to treat depressed bipolar patients. The main focus of this study is the comparison of these two medicati...

What is the current status of trial NCT00384332?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2007-01. Estimated completion is 2010-03.

What interventions are being tested in trial NCT00384332?

The interventions under investigation include: orally-disintegrating olanzapine (DRUG), regular olanzapine (DRUG).

Who is sponsoring clinical trial NCT00384332?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.